Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.80 USD
+0.04 (2.27%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $1.73 -0.07 (-3.89%) 7:34 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fortress Biotech (FBIO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$24.74 | $59.97 | $5.00 | 1,381.44% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Fortress Biotech comes to $24.74. The forecasts range from a low of $5.00 to a high of $59.97. The average price target represents an increase of 1% from the last closing price of $1.67.
Analyst Price Targets (4 )
Broker Rating
Fortress Biotech currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/20/2024 | Cantor Fitzgerald & Co | Jennifer Kim | Strong Buy | Strong Buy |
4/9/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
3/19/2024 | Alliance Global Partners | Research Department | Not Available | Strong Buy |
3/15/2024 | Roth Capital Partners | Jason Wittes | Not Available | Strong Buy |
3/15/2024 | The Benchmark Company | Robert Wasserman | Strong Buy | Strong Buy |
11/1/2023 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $24.74 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 82 of 252 |
Current Quarter EPS Est: | -1.32 |